Class Action Filed Against Aquestive Therapeutics Over Anaphylm Drug Application Disclosures

Rosen Law Firm, a top-ranked securities litigation firm, has filed a class action lawsuit against Aquestive Therapeutics, Inc. ($AQST) on behalf of investors who purchased the company's securities during a critical eight-month period. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application (NDA) for Anaphylm, a sublingual film treatment, while allegedly concealing or minimizing significant human factors issues related to the drug's packaging, use, administration, and labeling. The legal action covers investors who purchased securities between June 16, 2025 and January 8, 2026, with eligible shareholders potentially entitled to compensation for losses incurred.

The Allegations and Legal Framework

The class action complaint centers on disclosure deficiencies in how Aquestive communicated details about Anaphylm to investors and regulators. According to the lawsuit, the company failed to adequately disclose or minimize the significance of human factors issues—critical concerns in pharmaceutical development that relate to how patients will actually interact with a drug product in real-world settings.

Key allegations include:

• False or misleading statements regarding the Anaphylm NDA submitted to the FDA
• Concealment or minimization of human factors complications in the sublingual film's design
• Failures in disclosing concerns related to:
  • Packaging design and usability
  • Administration instructions and patient clarity
  • Labeling accuracy and comprehensiveness
  • Overall use environment considerations

For pharmaceutical companies, human factors analysis is a regulatory requirement that has gained increased scrutiny from the FDA in recent years. These analyses examine whether patients can safely and effectively use a medication as intended, and deficiencies in this area can result in regulatory delays, rejections, or post-market safety issues.

Market Context and Industry Implications

The timing of this lawsuit reflects broader regulatory and market pressures facing biopharmaceutical companies in the specialty pharma space. Aquestive Therapeutics focuses on innovative drug delivery systems, particularly for acute care medications. The company's development of Anaphylm—an alternative to traditional epinephrine auto-injectors for anaphylaxis treatment—represented a significant product opportunity in a competitive market segment.

The alleged disclosure failures during the June 2025 to January 2026 period are particularly notable because they coincide with critical NDA review phases. During this timeframe, investors would have relied on company communications to assess:

• The likelihood of FDA approval
• Potential regulatory timeline delays
• Competitive positioning versus existing treatments
• Revenue projections and market potential

The sublingual film delivery mechanism for anaphylaxis treatment is novel, which increases regulatory scrutiny around human factors. Unlike conventional auto-injectors that patients may be familiar with, a sublingual film requires different administration steps, patient education, and packaging considerations—all areas flagged in the lawsuit.

In the competitive landscape, Aquestive faces established players in emergency anaphylaxis treatment, including producers of traditional epinephrine auto-injectors. Any regulatory or safety concerns could significantly impact the drug's commercial viability and the company's valuation.

Investor Implications and Legal Recourse

This class action has meaningful implications for $AQST shareholders and the broader market's perception of the company's regulatory disclosure practices:

For Affected Shareholders:

• Investors who purchased Aquestive securities between June 16, 2025 and January 8, 2026 may qualify as class members
• Potential compensation available for documented losses during the class period
• Rosen Law Firm is encouraging eligible investors to secure counsel before important legal deadlines
• Class membership is typically automatic—shareholders need not take action to participate, but must meet purchase criteria

Broader Market Implications:

This litigation highlights the critical importance of regulatory disclosure compliance in biopharmaceutical companies, particularly regarding:

• Human factors analysis completeness and transparency
• NDA submission accuracy and comprehensive disclosure
• Risk communication to investors about regulatory challenges
• Investor reliance on company statements during drug development phases

The lawsuit could result in significant financial exposure for Aquestive, including settlement costs, legal fees, and potential impacts on the company's ability to raise capital or pursue partnerships. Additionally, regulatory agencies may scrutinize the company's future submissions more carefully, potentially extending approval timelines.

For the broader pharmaceutical industry, this case reinforces that disclosure deficiencies—particularly regarding regulatory submissions and human factors issues—can expose companies to substantial litigation risk. Institutional investors have increasingly focused on governance and disclosure quality at biotech companies, making this type of case material to investment decisions.

Looking Forward

As the legal process unfolds, attention will focus on several factors: the strength of evidence regarding alleged misstatements, the scope of the class membership, potential settlement negotiations, and the ultimate regulatory status of Anaphylm. The FDA's final decision on the Anaphylm NDA will be crucial context for evaluating damages.

For Aquestive Therapeutics shareholders, this development introduces legal and financial uncertainty during a period when the company's focus should be on drug development and commercialization. The class action underscores the heightened scrutiny that specialty pharmaceutical companies face regarding disclosure practices, particularly when regulatory pathways involve novel delivery mechanisms and complex human factors considerations. Investors in $AQST and similar companies should monitor both the litigation progress and any updates regarding Anaphylm's regulatory status, as both factors could materially impact shareholder value in coming months.